Arrowhead Pharmaceuticals (NASDAQ:ARWR) Receives “Outperform” Rating from Royal Bank of Canada
Royal Bank of Canada reissued their outperform rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $42.00 price target on the biotechnology company’s stock. A number of other brokerages also recently issued reports on ARWR. StockNews.com upgraded Arrowhead Pharmaceuticals to […]
Royal Bank of Canada reissued their outperform rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $42.00 price target on the biotechnology company’s stock. A number of other brokerages also recently issued reports on ARWR. StockNews.com upgraded Arrowhead Pharmaceuticals to […]
